Ratings
0
Nobody has rated this yet. Be the first!
Works
2
Efficacy and safety of alirocumab in reducing lipids and cardiovascular events
PCSK9 inhibition-mediated reduction in Lp(a) with evolocumab: an analysis of 10 clinical trials and the LDL receptor's role
